You are here: Industry Insights > gilead

News List

Gilead scouting for partners in India, Pak for remdesivir expresspharma
May 08, 2020
Recent clinical trial results and the decision by the US Food and Drug Administration (FDA) to issue ”Emergency Use Authorisation” for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally.
Gilead’s anti-viral remdesivir may be found effective against coronavirus expresspharma
May 06, 2020
The company is in discussions with some of the world’s leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022.
Gilead files lawsuit against US federal government over alleged contract breaches europeanpharmaceuticalreview
May 05, 2020
Gilead’s complaint alleges five contract breaches by the US Centers for Disease Control and Prevention (CDC) and seeks a declaration of contract breach and damages.
Gilead Granted EUA for Remdesivir in COVID-19 contractpharma
May 04, 2020
Facilitates broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease.
Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies pharmaceutical-business-review
April 26, 2020
Gilead Sciences and its subsidiary Kite have joined forces with oNKo-innate to discover and develop cancer immunotherapies focused on natural killer (NK) cells.
Gilead says leaked Covid-19 trial data of remdesivir inconclusive Pharmaceutical-Technology.
April 26, 2020
Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data the World Health Organization (WHO) accidentally posted on its website.
Trial of Gilead’s potential coronavirus treatment running ahead of schedule – researcher expresspharma
April 26, 2020
Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy and Infectious Diseases (NIAID), could come even sooner, lead researcher Dr Andre Kalil told Reuters.
WHO prematurely publishes remdesivir results pharmatimes
April 24, 2020
The World Health Organisation has accidentally leaked disappointing data from a trial of Gilead's coronavirus hopeful remdesivir in China.
Gilead disputes report that its drug flopped in leaked coronavirus trial expresspharma
April 24, 2020
In the Chinese trial remdesivir, given by intravenous infusion, failed to improve patients’ condition or reduce the pathogen’s presence in the bloodstream, according to draft documents published accidentally by the World Health Organization (WHO).
Gilead’s remdesivir prevents Covid-19 progression in preclinical study pharmaceutical-technology
April 21, 2020
A preclinical study in the US found that Gilead Sciences’ antiviral drug candidate remdesivir prevented disease progression in rhesus macaques monkeys with Covid-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page